Anxiety disorders: A review of tricyclic antidepressants and selective serotonin reuptake inhibitors

Acta Psychiatrica Scandinavica, Supplement

Volumn 101, Issue 403, 2000, Pages 39-49

  Zohar, J ^a   Westenberg, H G M ^b  

^a TEL AVIV UNIVERSITY   (Israel)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Anxiety disorder; SSRI; TCA

Indexed keywords

ALPRAZOLAM; AMITRIPTYLINE; AMOXAPINE; BENZODIAZEPINE DERIVATIVE; CITALOPRAM; CLOMIPRAMINE; CLONAZEPAM; DESIPRAMINE; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; MAPROTILINE; NORTRIPTYLINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT;

ANXIETY NEUROSIS; CONFERENCE PAPER; DRUG CHOICE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; OBSESSION; PANIC; POSTTRAUMATIC STRESS DISORDER; SOCIAL PHOBIA; ANXIETY DISORDER; OBSESSIVE COMPULSIVE DISORDER; PHOBIA; REVIEW; TREATMENT OUTCOME;

ANTIDEPRESSIVE AGENTS, TRICYCLIC; ANXIETY DISORDERS; HUMANS; OBSESSIVE-COMPULSIVE DISORDER; PHOBIC DISORDERS; SEROTONIN UPTAKE INHIBITORS; STRESS DISORDERS, POST-TRAUMATIC; TREATMENT OUTCOME;

EID: 0034565212     PISSN: 00651591     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0447.2000.tb10947.x     Document Type: Conference Paper

References (121)

1. One-month prevalence of mental disorders in the United States: Based on five epidemiologic catchment area sites
2. Theoretical and therapeutic considerations for the anxiety disorders
3. A practical update on anxiety disorders and their pharmacologic treatment
4. Serotonin receptor specificity in anxiety disorders
5. The spectrum of behaviors influenced by serotonin
6. A risk-benefit assessment of pharmacological treatments for panic disorder
7. Quality of life in panic disorder
8. Panic disorder and quality of life: Variables predictive of functional impairment
9. Panic disorder, comorbidity, and suicide attempts
10. High-potency benzodiazepines for short-term management of panic disorder: The U.S. experience
11. Alprazolam plasma concentrations and treatment response in panic disorder and agoraphobia
12. Alprazolam dependency: Use of clonazepam for withdrawal
13. Secondary depression in panic disorder and agoraphobia. I. Frequency, severity, and response to treatment
14. Benzodiazepine treatment of panic and agoraphobic symptoms: Use, dependence, toxicity, abuse
15. New findings in the treatment of panic disorder
16. Developments in the drug treatment of panic disorder: What is the place of the selective serotonin reuptake inhibitors?
17. Diagnostic dilemmas presented by patients with anxiety and depression
18. Anxiety symptom relief in depression treatment outcomes
19. Treating comorbid depression and anxiety
20. Feeling hopeless and helpless: When anxiety symptoms coexist with depressive disorder
21. Management of patients with depression associated with anxiety symptoms
22. Antidepressant withdrawal reactions
23. Outcome assessment and clinical improvement in panic disorder: Evidence from a randomized controlled trial of fluoxetine and placebo
24. Effect of serotonin uptake inhibitors in anxiety disorders; a double-blind comparison of clomipramine and fluvoxamine
25. Serotonin function in panic disorder: A double blind placebo controlled study with fluvoxamine and ritanserin
26. A comparison of fluvoxamine, cognitive therapy, and placebo in the treatment of panic disorder
27. Paroxetine in the treatment of panic disorder. A randomised, double-blind, placebo-controlled study
28. Double-blind, fixed-dose, placebo-controlled study of paroxetine in the treatment of panic disorder
29. Paroxetine, clomipramine and placebo in the treatment of panic disorder
30. The effect of citalopram in panic disorder
31. Sertraline in the treatment of panic disorder. A multi-site, double-blind, placebo-controlled, fixed-dose investigation
32. Sertraline in the treatment of panic disorder: A double-blind multicenter trial
33. Effect of the selective serotonin reuptake inhibitor fluvoxamine on CCK-4 induced panic attacks
34. Serotonin uptake inhibitors are superior to imipramine and alprazolam in alleviating panic attacks: A meta-analysis
35. The role of SSRIs in panic disorder
36. Combined pharmacotherapy and cognitive behavior therapy in the treatment of panic disorder
37. The epidemiology of obsessive-compulsive disorder in five US communities
38. Use of monochlorimipramine in psychiatric patients who are resistant to other therapy in Spanish
39. The action of chlorimipramine in obsessive-compulsive neurosis: A pilot study
40. Preliminary results from a multicenter trial of clomipramine in obsessive-compulsive disorder
41. Clomipramine treatment of obsessive-compulsive disorder. I. A controlled clinical trial
42. Clomipramine treatment of childhood obsessive-compulsive disorder. A double-blind controlled study
43. Double-blind comparative study of clomipramine and amitriptyline in obsessive neurosis
44. Imipramine and placebo in the treatment of obsessive-compulsives: Their effect on depression and on obsessional symptoms
45. Treatment of childhood obsessive compulsive disorder with clomipramine and desmethylimipramine: A double-blind crossover comparison
46. Obsessive-compulsive disorder: Psychobiological approaches to diagnosis, treatment, and pathophysiology
47. The relationship of plasma clomipramine and N-desmethylclomipramine to response in obsessive-compulsive disorder
48. Open trial of fluoxetine in obsessive-compulsive disorder
49. Fluoxetine treatment of obsessive-compulsive disorder: An open clinical trial
50. A double-blind, placebo-controlled study of fluoxetine in patients with DSM-III-R obsessive-compulsive disorder
51. A multicenter investigation of fixed-dose fluoxetine in the treatment of obsessive-compulsive disorder
52. Efficacy of fluvoxamine in obsessive-compulsive disorder. A double-blind comparison with placebo
53. Double-blind parallel comparison of three dosages of sertraline and placebo in outpatients with obsessive-compulsive disorder
54. Paroxetine versus clomipramine in the treatment of obsessive-compulsive disorder
55. Specificity of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder. Comparison of fluvoxamine and desipramine
56. SSRIs in the treatment of obsessive-compulsive disorder
57. Recent developments in the psychopharmacology of anxiety disorders
58. Pharmacotherapy for obsessive-compulsive disorder
59. Exposure therapy, fluvoxamine, or combination treatment in obsessive-compulsive disorder: One-year followup
60. Behavioral psychotherapy for children and adolescents with obsessive-compulsive disorder: An open trial of a new protocol-driven treatment package
61. Post-traumatic stress disorder in the general population. Findings of the epidemiologic catchment area survey
62. Posttraumatic stress disorder in the National Comorbidity Survey
63. Comorbidity in post-traumatic stress disorder: An analysis of community and clinical studies
64. Psychoneuroendocrine assessment of posttraumatic stress disorder: Current progress and new directions
65. The psychobiology of posttraumatic stress disorder
66. Treatment of post-traumatic stress disorder with amitriptyline and placebo
67. A controlled trial of desipramine in 18 men with posttraumatic stress disorder
68. A randomized clinical trial of phenelzine and imipramine for posttraumatic stress disorder
69. Pharmacotherapy for posttraumatic stress disorder using phenelzine or imipramine
70. An open trial of fluoxetine in the treatment of posttraumatic stress disorder
71. Open prospective trial of fluoxetine for posttraumatic stress disorder
72. Fluoxetine in posttraumatic stress disorder
73. Fluoxetine in post-traumatic stress disorder
74. Sertraline in the treatment of rape victims with posttraumatic stress disorder
75. Sertraline treatment of comorbid posttraumatic stress disorder and alcohol dependence
76. An open trial of paroxetine in patients with noncombat-related, chronic posttraumatic stress disorder
77. Post traumatic stress disorder
78. Management of posttraumatic stress disorder; diagnostic and therapeutic issues
79. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey
80. Identification of cases of anxiety disorders and affective disorders in the community according to ICD-10 and DSM-III-R by using the composite International Diagnostic Interview (CIDI)
81. The nature of social anxiety disorder
82. Phenelzine in phobic anxiety: A controlled trial
83. Behaviour therapy versus drug therapy in the treatment of phobic neurosis
84. A clinical trial of phenelzine in anxiety depressive and phobic neuroses
85. Pharmacotherapy of social phobia. A controlled study with moclobemide and phenelzine
86. Moclobemide in social phobia. A double-blind, placebo-controlled clinical study
87. Moclobemide in social phobia: A controlled dose-response trial
88. Social phobia. Comorbidity and morbidity in an epidemiologic sample
89. Psychopharmacological treatment of social phobia: Clinical and biochemical effects of brofaromine, a selective MAO-A inhibitor
90. Social phobia: The clinical efficacy and tolerability of the monoamine oxidase A and serotonin uptake inhibitor brofaromine. A double-blind placebo-controlled study
91. Brofaromine for social phobia: A multicenter, placebo-controlled, double-blind study
92. Cognitive-behavioral and pharmacological treatments of social phobia. A controlled study
93. Treatment of social phobia with clonazepam and placebo
94. Paroxetine treatment of generalized social phobia (social anxiety disorder): A randomized controlled trial
95. Paroxetine in the treatment of generalized social phobia: Open-label treatment and double-blind placebo-controlled discontinuation
96. Implications of the severity of social phobia
97. Paroxetine in social phobia
98. Fluoxetine efficacy in social phobia
99. Clinical effects of buspirone in social phobia: A double-blind placebo- controlled study
100. Sertraline in social phobia
101. Use of the selective serotonin reuptake inhibitor citalopram in the treatment of generalized social phobia
102. Psychopharmacological treatment of social phobia; a double blind placebo controlled study with fluvoxamine
103. Fluvoxamine treatment of social phobia: A double-blind, placebo-controlled study
104. Paroxetine in social phobia
105. Quality of life and psychiatric morbidity in panic disorder and generalized anxiety disorder
106. The long-term management of generalized anxiety disorder: Issues and dilemmas
107. Strategies for treatment of generalized anxiety in the primary care setting
108. Treatment of generalized anxiety disorder: Preliminary clinical experience with buspirone
109. Differential effects of alprazolam and imipramine in generalized anxiety disorder: Somatic versus psychic symptoms
110. Antidepressants for the treatment of generalized anxiety disorder. A placebo-controlled comparison of imipramine, trazodone, and diazepam
111. Imipramine and chlordiazepoxide in depressive and anxiety disorders. II. Efficacy in anxious outpatients
112. Clomipramine treatment for generalized anxiety disorder
113. Changes on the temperament and character inventory after paroxetine treatment in volunteers with generalized anxiety disorder
114. Paroxetine efficacy in the treatment of generalized anxiety disorder
115. Fluoxetine, placebo, and tricyclic antidepressants in major depression with and without anxious features
116. Comorbid anxious signs and symptoms in major depression: Impact on functional work capacity and comparative treatment outcomes
117. Should anxiety and insomnia influence antidepressant selection: A randomized comparison of fluoxetine and imipramine
118. Major agitated-anxious versus blunted-retarded depression: Differential effects of fluoxetine in French